Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same author

Call For Papers: Molecular Understanding and Formulation Design for Peptide Delivery.

Molecular pharmaceutics·2026
Same author

Prediction of Tacrolimus-Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models.

Pharmaceutics·2026
Same author

Research progress of depression and pain comorbidity: Animal model, mechanism, treatment strategy.

Brain research bulletin·2026
Same author

Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting-based retrospective cohort study.

BMC infectious diseases·2026
Same author

Long-term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large-cohort retrospective study.

British journal of haematology·2026

Related Experiment Video

Updated: May 21, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Model-informed vancomycin precision dosing by population pharmacokinetics combined with machine learning algorithms.

Lei Shi1, Nan Hu1, Jing Ling1

  • 1Department of Pharmacy, The Third Affiliated Hospital of Soochow University/The First People's Hospital of Changzhou, Changzhou, China.

British Journal of Clinical Pharmacology
|May 20, 2026
PubMed
Summary
This summary is machine-generated.

A new artificial neural network (ANN) model accurately predicts vancomycin 24-h area under the curve (AUC), optimizing therapeutic drug monitoring (TDM) and improving patient outcomes. This machine learning approach enhances individualized dosing and reduces toxicity.

Keywords:
area under curvemachine learningpopulation pharmacokineticstherapeutic drug monitoringvancomycin

Related Experiment Videos

Last Updated: May 21, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Area of Science:

  • Pharmacology and Machine Learning
  • Clinical Pharmacokinetics
  • Drug Monitoring and Optimization

Background:

  • Vancomycin therapeutic drug monitoring (TDM) faces challenges in achieving target AUC/MIC ratios with traditional dosing.
  • Suboptimal outcomes and toxicity are common due to difficulties in individualized vancomycin regimens.

Purpose of the Study:

  • To develop and validate a novel population pharmacokinetic (PopPK)-informed machine learning model for optimizing vancomycin TDM.
  • To accurately predict the 24-h AUC for rapid, individualized dose adjustments.
  • To improve target attainment, reduce regimen modifications, and minimize vancomycin toxicity.

Main Methods:

  • Analysis of 1140 vancomycin TDM samples to develop and compare five machine learning models.
  • Performance evaluation using R², RMSE, Lin's CCC, MPE, and MAPE.
  • Validation of the top-performing Artificial Neural Network (ANN) model using SHAP analysis, Bland-Altman plots, error grid analysis, and ROC curves.

Main Results:

  • The ANN (MLP) model demonstrated superior performance with R² of 0.920 ± 0.027 and CCC of 0.960 ± 0.011.
  • The model achieved the lowest RMSE (0.498 ± 0.076 L/h) and minimal systematic bias (MPE: 1.290 ± 1.774).
  • SHAP analysis identified measured concentration (DV), Cys (mg/L), and last dose as key predictive features.

Conclusions:

  • The ANN model offers exceptional accuracy, robustness, and clinical safety in predicting individualized vancomycin clearance.
  • This model can be deployed as a point-of-care clinical decision support (CDSS) tool.
  • It presents a novel solution to enhance accessibility and accuracy in routine TDM practices.